​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $68.17, with a high of $82.00 and a low of $60.00. This represents a 88.31% increase from the last price of $36.20.

$25 $37 $49 $61 $73 $85 High: $82 Avg: $68.17 Low: $60 Last Closed Price: $36.2

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 1 Strong Buy (6.25%), 14 Buy (87.50%), 1 Hold (6.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 14 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines88.31%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts1111
Avg Price Target$64.00$64.00$62.18
Last Closing Price$36.20$36.20$36.20
Upside/Downside76.80%76.80%71.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25410---14
Mar, 25510---15
Feb, 25510---15
Jan, 25510---15
Dec, 24510---15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 01, 2025Benjamin BurnettStifel Nicolaus$64.00$33.6290.36%76.80%
Jan 08, 2025Eliana MerleUBS$71.00$44.3360.16%96.13%
Nov 07, 2024Joseph CatanzaroPiper Sandler$70.00$56.0924.80%93.37%
Nov 04, 2024Raghuram SelvarajuH.C. Wainwright$62.00$55.8710.97%71.27%
Oct 28, 2024Michael SchmidtGuggenheim$82.00$46.9674.62%126.52%
Oct 28, 2024Jay OlsonOppenheimer$60.00$46.8328.12%65.75%
Oct 15, 2024Jay OlsonOppenheimer$55.00$49.2211.74%51.93%
Sep 17, 2024Joseph CatanzaroPiper Sandler$57.00$44.2428.84%57.46%
Aug 08, 2024Ami FadiaNeedham$61.00$42.7342.76%68.51%
Jul 15, 2024Robert DriscollWedbush$59.00$47.0125.51%62.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025UBSBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 28, 2024NeedhamBuyBuyhold
Oct 15, 2024OppenheimerOutperformOutperformhold
Sep 27, 2024BarclaysOverweightOverweighthold
Sep 17, 2024Piper SandlerOverweightOverweighthold
Aug 08, 2024NeedhamBuyBuyhold
Jul 18, 2024BarclaysOverweightOverweighthold
Jul 16, 2024Piper SandlerOverweightNeutraldowngrade
Jul 16, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.62$-2.47$-3.08$-3.86$-3.58----
Avg Forecast$-1.83$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-1.83$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-1.83$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-11.48%-1.20%-6.38%10.92%3.17%----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.98M$29.39M$35.38M$11.58M-----
Avg Forecast$50.97M$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$50.97M$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$50.97M$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %-15.66%2.11%26.98%-8.47%-----

Net Income Forecast

$-700M $-520M $-340M $-160M $20M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-108.16M$-179.77M$-248.71M$-436.37M$-600.09M----
Avg Forecast$-206.61M$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-206.61M$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-206.61M$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %-47.65%6.98%33.30%-44.83%----

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 14 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 16 Wall Street analysts, averages $68.17 over the next 12 months. The price target range spans from $60 at the low end to $82 at the high end, suggesting a potential 88.31% change from the previous closing price of $36.2.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 88.31% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • April 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.93, marking a 9.78% increase from the reported $-3.58 in 2024. Estimates for the following years are $-4.05 in 2026, $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2025 is $5.87M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $19.77M, followed by $178.13M for 2027, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2025 stands at $-470M, representing a -21.75% decrease from the reported $-600M in 2024. Projections indicate $-396M in 2026, $-609M in 2027, and $-187M in 2028.